Alyeska Investment Group
OVID icon

Alyeska Investment Group’s Ovid Therapeutics OVID Stock Holding History

Alyeska Investment Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-225,000
Closed -$398K – 502
2019
Q1 		$398K Buy
+225,000
New +$563K 0.01% 353

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $110M AUM 44.24% 1-Year Est. Return

Alyeska Investment Group's OVID Position: Q2 2019 in Review

Alyeska Investment Group sold out of Ovid Therapeutics (OVID) in Q2 2019, closing a stake of 225,000 shares — an estimated $398K sold.

Alyeska Investment Group first reported a position in OVID in Q1 2019 and held it in 1 quarter. The position peaked at $398K in Q1 2019. 35 funds tracked by Wall St. Rank hold OVID as of Q2 2019.

  • Alyeska Investment Group reported no remaining Ovid Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 225,000 Ovid Therapeutics shares in Q2 2019, an estimated $398K.
  • Alyeska Investment Group first reported a position in Ovid Therapeutics in Q1 2019 and held it in 1 quarter.
  • Alyeska Investment Group's Ovid Therapeutics position peaked at $398K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2019.

Based on Alyeska Investment Group's 13F filing for Q2 2019, filed 14 Aug 2019.